An Experimental Drug Protects Covid-19 Patients, Eli Lilly Claims

 

A single infusion of an experimental drug markedly reduced levels of the coronavirus in newly infected patients and lowered the chances that they would need hospitalization, the drug’s maker announced on Wednesday.
The drug is a monoclonal antibody, a manufactured copy of an antibody produced by a patient who recovered from Covid-19, the illness caused by the coronavirus. Many scientists hope that monoclonal antibodies will prove to be powerful treatments for Covid-19, but they are difficult and expensive to manufacture, and progress has been slow.
The announcement, by Eli Lilly, was not accompanied by detailed data; independent scientists have not yet reviewed the results, nor have they been published in a peer-reviewed journal. The findings are the interim results of an ongoing trial.

Διαβάστε περισσότερα:

https://www.nytimes.com/2020/09/16/health/coronavirus-drug-eli-lilly.html?smid=tw-nytimesscience&smtyp=cur